Actuate Therapeutics, Inc.
NASDAQActuate Therapeutics arrives at its May 21 update in the worst position a clinical-stage biotech can be in: the stock is down 21% on the week to $2.62, the sole analyst covering it has been cutting targets, and the company carries no revenue against a projected net loss of roughly $23 million for the year. The recent price damage is severe and concentrated. ACTU shed nearly 10% in…
Snapshot as of 20 May 2026
Actuate Therapeutics arrives at its May 21 update in the worst position a clinical-stage biotech can be in: the stock is down 21% on the week to $2.62, the sole analyst covering it has been cutting targets, and the…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ACTU — free to start on ORTEX.
Sign up for free →Open ACTU on ORTEX